Professor Thierry Facon presents MAIA-study

Name: Professor Thierry Facon presents MAIA-study
Uploaded: 2021-11-25T12:55:50.424Z
Description: A phase 3 randomised study of daratumumab plus lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant. CP-130012 DARZALEX® (DARATUMUMAB) short SPC, click here

‌
‌

A phase 3 randomised study of daratumumab plus lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant.

CP-130012

DARZALEX^® (DARATUMUMAB) short SPC, click here

CP-130489